Every week, a new AI drug discovery startup announces a breakthrough. But are they real? The small molecule drug discovery market research study shows that computational drug design is the fastest‑growing technology, with a CAGR above 12%. AI can screen billions of molecules in silico, predict toxicity, and optimise binding affinity. But AI‑generated molecules still need to be synthesised and tested in the lab — and many fail.

What's working? AI for lead optimisation — taking a weak hit and making it more potent. Also, AI for predicting ADME (absorption, distribution, metabolism, excretion) properties. The small molecule drug discovery market trends highlight that the fastest‑growing end‑user segment is contract research organizations (CROs), which are adopting AI to offer faster, cheaper services to biotechs.

But AI is not magic. It's only as good as the data it's trained on. And clinical trials are still the bottleneck.

The bottom line: AI is a powerful tool, but it won't replace medicinal chemists. It will make them much more productive.